Stockscreener 앱 받기
5.60
4.92%
-0.29
시간 외 거래:
5.60
Aardvark Therapeutics Inc 주식(AARD)의 최신 뉴스
Aardvark Therapeutics Halts HERO Trial Amid Safety Concerns - Intellectia AI
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - PR Newswire
Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - marketscreener.com
Number of shareholders of Aardvark Therapeutics, Inc. – NASDAQ:AARD - TradingView
AARD Forecast, Price Target & Analyst Ratings | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid - GlobeNewswire
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Why Aardvark Therapeutics just lost more than half its value - MSN
AARD (Aardvark Therapeutics Inc.) posts narrower Q4 2025 loss than expected, sending shares nearly 5 percent higher.Institutional Grade Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Aardvark Therapeutics Shares Plummet After Trial Halt - Intellectia AI
Repeat: Norsk Hydro: Reminder – Invitation to Hydro’s first quarter results 2026 - Weekly Voice
AARD Stock Price and Chart — NASDAQ:AARD - TradingView
Aardvark (AARD) Stock Mega Cap Focus (Trend Weakens) 2026-04-16Expert Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Large Decline in Short Interest - MarketBeat
AARD Technical Analysis & Stock Price Forecast - Intellectia AI
AARD Options Chain — NASDAQ:AARD - TradingView
AARD Options Volatility — NASDAQ:AARD - TradingView
Aardvark Therapeutics Halts HERO Trial, Shares Plunge 56% - Intellectia AI
Aardvark Therapeutics Shares Plunge After Trial Halt - Intellectia AI
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman - GlobeNewswire Inc.
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Prader-Willi Syndrome Market Size in the 7MM was ~USD 600 million in 2023 and expected to grow by 2034, reveals DelveInsight - Barchart.com
[EFFECT] Aardvark Therapeutics, Inc. SEC Filing - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aardvark Therapeutics, Inc. (AARD) And Encourages Shareholders to Reach Out | NDAQ:AARD | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Aardvark Therapeutics (AARD) price target decreased by 43.62% to 18.77 - MSN
Aardvark ups to $150M ATM sale with Piper Sandler (NASDAQ: AARD) - stocktitan.net
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aardvark Therapeutics, Inc. (AARD) And Encourages Investors to Connect - ACCESS Newswire
Why Aardvark Therapeutics (AARD) paused late-stage ARD-101 trials after cardiac findings - msn.com
Bronstein, Gewirtz & Grossman, LLC Encourages Aardvark Therapeutics, Inc. (AARD) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aardvark Therapeutics, Inc. (AARD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings - Insider Monkey
Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Significant Drop in Short Interest - MarketBeat
Why is Aardvark Therapeutics stock sinking Monday? - MSN
Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
US Stocks Recap: Does Aardvark Therapeutics Inc align with a passive investing strategyWeekly Risk Report & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Heart activity changes prompted pause in trial of ARD-101 in PWS - Prader-Willi Syndrome News
1.87%
1.17%
자본화:
|
볼륨(24시간):